SCHEMBL301164

SCHEMBL301164

Cc1ccc(P(c2ccc(C)cc2)c2cccc(C)c2-c2c(C)cccc2P(c2ccc(C)cc2)c2ccc(C)cc2)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
DRD1 P21728 2/20 0.33
CYP1A2 P05177 4/20 0.32
CYP2A6 P11509 2/20 0.32
CD44 P16070 1/20 0.32
TOP1 P11387 2/20 0.32
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA7 P43166 2/20 0.31
CA9 Q16790 2/20 0.31
CA12 O43570 1/20 0.31
CA3 P07451 1/20 0.31
CA6 P23280 1/20 0.31
CA5A P35218 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
ALDH1A1 P00352 3/20 0.31
TSHR P16473 1/20 0.31
KMT2A Q03164 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31566349 1.00 ACHE (0.33) ACHETDP1DRD1CYP1A2CYP2A6
Hydrochloric Acid SCHEMBL3452951 0.96 DRD1 (0.31) ACHETDP1DRD1CYP1A2CYP2A6
SCHEMBL8523408 0.89
SCHEMBL28825736 0.87 MYC (0.35) DRD1TOP1CA1CA2CA7
SCHEMBL29366742 0.85 TDP1 (0.46) ACHETDP1DRD1CYP1A2CYP2A6
SCHEMBL301645 0.85 TDP1 (0.46) ACHETDP1DRD1CYP1A2CYP2A6
SCHEMBL30142870 0.85 TDP1 (0.46) ACHETDP1DRD1CYP1A2CYP2A6
SCHEMBL7783641 0.84 ALDH1A1 (0.34) DRD1CYP1A2CYP2A6CD44ALDH1A1
Hydrochloric Acid SCHEMBL15205656 0.84
SCHEMBL12394364 0.83 TDP1 (0.44) ACHETDP1DRD1CYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436181-B2 Production process of optically active 3-quinuclidinol derivative NIPPON SODA CO., LTD. (JP) 2013-05-07 US claimed
EP-1840116-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE BETA-HYDROXY-ALPHA-AMINOCARBOXYLIC ACID DERIVATIVE NISSAN CHEMICAL IND LTD (JP) 2012-10-03 EP claimed
US-7781609-B2 Process for producing optically active β-hydroxy-α-aminocarboxylic acid derivative NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-08-24 US claimed
US-20080139825-A1 Process For Producing Optically Active Beta-Hydroxy-Alpha-Aminocarboxylic Acid Derivative NISSAN CHEMICAL INDUSTRIAL, LTD. (JP) 2008-06-12 US claimed
EP-1840116-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE BETA-HYDROXY-ALPHA-AMINOCARBOXYLIC ACID DERIVATIVE Nissan Chemical Industries, Ltd. (JP) 2007-10-03 EP claimed
EP-1650207-B1 Process for producing optically active 3-quinuclidinols TAKASAGO PERFUMERY CO LTD (JP) 2007-06-27 EP claimed
US-6069245-A PRODUCING A 3-BENZOYLAMINO-4-BENZOYLOXYHEXAHYDROAZEPINE BY THE CATALYTIC HYDROGENATION OF THE 4-OXO-AMINE SALT DERIVATIVE; PROTECTING THE RING NITROGEN; FORMING A FUSED RING; HYDROLYSIS; ACYLATION AND DEPROTECTING HOFFMANN-LA ROCHE INC. (US) 2000-05-30 US claimed
US-5919962-A CATALYST TAKASAGO INTERNATIONAL CORPORATION (JP) 1999-07-06 US claimed
US-5902882-A ASYMMETRICALLY HYDROGENATING AN AZEPINE COMPOUND IN THE PRESENCE OF A RUTHENIUM-DIPHOSPHINE COMPLEX CATALYST HOFFMANN-LA ROCHE INC. (US) 1999-05-11 US claimed
EP-0802190-A1 Process and intermediates for preparing azepines F. HOFFMANN-LA ROCHE AG (CH) 1997-10-22 EP claimed
EP-0492401-B1 Asymmetric hydrogenation CIBA GEIGY AG (CH) 1996-01-24 EP claimed
US-20220169600-A1 METHOD FOR PRODUCING PKROSTAGLANDIN KYOWA PHARMA CHEMICAL CO., LTD. (JP) 2022-06-02 US disclosed
EP-3950672-A1 METHOD FOR PRODUCING PKROSTAGLANDIN Kyowa Pharma Chemical Co., Ltd. (JP) 2022-02-09 EP disclosed
US-10294193-B2 Compound, and flavor composition and/or fragrance composition containing same TAKASAGO INTERNATIONAL CORPORATION (JP) 2019-05-21 US disclosed
EP-3199513-B1 PROCESS FOR PRODUCING ALCOHOL ANALOGUE TAKASAGO PERFUMERY CO LTD (JP) 2019-05-08 EP disclosed
EP-0392389-A2 Process for the preparation of vinyl compounds F. HOFFMANN-LA ROCHE AG (CH) 1990-10-17 EP disclosed
US-4861890-A Isomerization HOFFMANN-LA ROCHE INC. (US) 1989-08-29 US disclosed
US-4857648-A Isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 1989-08-15 US disclosed
US-4556740-A Phosphorus compounds HOFFMANN-LA ROCHE INC. (US) 1985-12-03 US disclosed
EP-0104375-A1 Phosphorus-containing biphenyl derivatives and their use in asymmetric hydrogenation and enatioselective hydrogen shifts F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169600-A1 METHOD FOR PRODUCING PKROSTAGLANDIN PTGS1, PTGER1, RACK1 ACHE 4264/4885TDP1 4061/4885DRD1 1207/4885
US-20080139825-A1 Process For Producing Optically Active Beta-Hydroxy-Alpha-Aminocarboxylic Acid Derivative HCAR2, HCAR1, ALDH7A1 ACHE 1015/4885TDP1 4714/4885DRD1 1118/4885
US-10294193-B2 Compound, and flavor composition and/or fragrance composition containing same FZD7, TAS1R1, TAS2R5 ACHE 1681/4885TDP1 4448/4885DRD1 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.